24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2020-02-26T10:44:55+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|0 Comments

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2019-12-10T12:04:11+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|0 Comments

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

23 01, 2018

TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

2019-12-09T09:17:20+01:00January 23rd, 2018|biomarkers, drug development, drug discovery, LMD, microRNA, microRNAs, Vivomicx|0 Comments

TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the [...]